DataMEDS AI, Inc. entered into an Amended and Restated Letter of Intent to acquire or exclusively license QOLPOM-related intellectual property from EOS Technology Holdings and Scilex Holding Company, expand its PharmacyChain license with Datavault AI Inc., and acquire a controlling interest in Tollo Health through an exchange of membership interests with HealthBridge Advisors. The transaction consideration involves issuing common stock such that the acquiring entities would hold approximately 84.6% of the company on a fully diluted basis, while existing public shareholders would retain roughly 10.4%. The deal is subject to due diligence, financing, and regulatory approvals, including potential Nasdaq listing requirements.
